Evaluating HER2 amplification and overexpression in breast cancer. - Wikidata - awgldk - TriplyDB

Evaluating HER2 amplification and overexpression in breast cancer.

Evaluating HER2 amplification and overexpression in breast cancer.

http://www.wikidata.org/entity/Q52936177

about

Prognostic relevance of disseminated tumor cells in the bone marrow and biological factors of 265 primary breast carcinomas.Her2 assessment using quantitative reverse transcriptase polymerase chain reaction reliably identifies Her2 overexpression without amplification in breast cancer cases.Investigating AP-2 and YY1 protein expression as a cause of high HER2 gene transcription in breast cancers with discordant HER2 gene amplification.Utilization of HER2 genetic testing in a multi-institutional observational study.Challenges to the translation of genomic information into clinical practice and health policy: Utilization, preferences and economic value.Confirmation of a low HER2 positivity rate of breast carcinomas - limitations of immunohistochemistry and in situ hybridization Deregulation of the EGFR/PI3K/PTEN/Akt/mTORC1 pathway in breast cancer: possibilities for therapeutic intervention.High expression of MAGE-A10 cancer-testis antigen in triple-negative breast cancer.Comparison between immunohistochemistry and chromogenic in situ hybridization in assessing HER-2 status in breast cancer.Enhanced SMYD3 expression is essential for the growth of breast cancer cells.Significance of human epidermal growth factor receptor 2 expression in colorectal cancer.Detection of HER2 amplification in circulating free DNA in patients with breast cancer.Genetic advances will influence the practice of medicine: examples from cancer research and care of cancer patients.Assessment of HER2 status in breast cancer: overall positivity rate and accuracy by fluorescence in situ hybridization and immunohistochemistry in a single institution over 12 years: a quality control study.High-density SNP arrays improve detection of HER2 amplification and polyploidy in breast tumors Evaluation of intratumoral HER-2 heterogeneity by fluorescence in situ hybridization in invasive breast cancer: a single institution study HER2 evaluation and its impact on breast cancer treatment decisions.Best Practice No 176: Updated recommendations for HER2 testing in the UK HER2 amplification status in breast cancer: a comparison between immunohistochemical staining and fluorescence in situ hybridisation using manual and automated quantitative image analysis scoring techniques.IHC for Her2 with CBE356 antibody is a more accurate predictor of Her2 gene amplification by FISH than HercepTest in breast carcinoma.Human epidermal growth factor receptor-2 gene amplification in gastric cancer using tissue microarray technology.Testing for HER2-positive breast cancer: a systematic review and cost-effectiveness analysis Chromogenic in situ hybridisation (CISH) should be an accepted method in the routine diagnostic evaluation of HER2 status in breast cancer External quality assurance of HER2 fluorescence in situ hybridisation testing: results of a UK NEQAS pilot scheme.Chromosome instability and benefit from adjuvant anthracyclines in breast cancer.AQUA and FISH analysis of HER-2/neu expression and amplification in a small cell lung carcinoma tissue microarray.Antibody therapy for early-stage breast cancer: trastuzumab adjuvant and neoadjuvant trials.Genetic aberrations of c-myc and CCND1 in the development of invasive bladder cancer.Agreement between chromogenic in situ hybridisation (CISH) and FISH in the determination of HER2 status in breast cancer.HER2/neu overexpression in the development of muscle-invasive transitional cell carcinoma of the bladder Is TIMP-1 immunoreactivity alone or in combination with other markers a predictor of benefit from anthracyclines in the BR9601 adjuvant breast cancer chemotherapy trial?Practical implications of gene-expression-based assays for breast oncologists.Phase III, double-blind, randomized study comparing lapatinib plus paclitaxel with placebo plus paclitaxel as first-line treatment for metastatic breast cancer HER-2 gene amplification in human breast cancer without concurrent HER-2 over-expression.Automated image analysis in histopathology: a valuable tool in medical diagnostics.A role for BRCA1 in sporadic breast cancer Her-2/neu testing and therapy in gastroesophageal adenocarcinoma.Anti-HER agents in gastric cancer: from bench to bedside.Clinical and health economic outcomes of alternative HER2 test strategies for guiding adjuvant trastuzumab therapy.HER-2 positive primary solid neuroendocrine carcinoma of the breast: a case report and review of the literature.

P2860

Q25257601-9012F27B-BDB7-4EE4-9C4A-AD02242661F2 Q33623561-4BFE6255-8E67-4D8F-8114-63FC7D2F4508 Q33627215-CFEEF8C0-79DC-421E-BF71-8EEF7F4FC82F Q33771243-59C944A3-5915-4C70-B2D7-6E667037B7F7 Q34022038-F3E22B10-D115-4444-B18B-FB7543C800C2 Q34071408-7DD907C2-BE47-43DE-8CB1-C96C85FF54A0 Q34103963-19AA50F1-2872-46AF-98C6-2F9C864A503F Q34235940-5562B4B9-1D47-4DEA-AC1B-FCF5F3B1B45A Q34424833-57A18ADE-CE85-4921-8397-3CB674A7F114 Q34488868-BE492368-7E4D-44E1-8248-8A7D8927FB72 Q34585338-3760EA8D-D7E1-4B4E-9E93-C7D4BD2B6851 Q34806810-9E0728D2-7FCC-4A6B-86E2-B220C6A0336F Q35051949-CA0A6E8A-3C6A-4185-8045-C3B2A5BC5DD5 Q35078787-B4300481-168D-44D5-B349-9334776A2E6B Q35078859-B10CF206-3CC3-4B59-B169-AF6E1258F400 Q35158754-48E9DBA2-D152-41AE-B109-7544AAED3056 Q35576343-B43A2F38-02FE-4366-A264-0514643BA6BF Q35587451-6E1667B0-DA5D-4BA4-9C75-4BD9BB5B7869 Q35588682-8DDFFB56-5765-487F-8454-3A34B1078CF1 Q35588768-EC20AD7E-D2B0-48DF-AF18-3126DEDC04AA Q35670454-C274FA6E-A989-4598-84C6-CA00AC6346DE Q35778406-9520A8B0-A4CD-491A-A525-34FF6DE18A02 Q35984470-496FBC8C-1A18-4489-A5FA-07AFB2FAE724 Q36017256-5214D977-246C-423E-B40D-2974CC771BA3 Q36075278-7FB27CFB-3B72-48B8-829F-E511E9067F18 Q36552052-5FCDD275-0328-4EED-9004-174CA3742D5A Q36569759-AE326868-96EF-4761-B961-DEB42EB71BD8 Q36624065-590F39AE-B9E6-439E-9ACA-A03F8DA08BC9 Q36648916-DC79797B-C8A3-4C66-8009-B7A609823BA6 Q36671182-F82AE931-1374-4F8C-8EE9-643BACCAC922 Q36903127-0D27C53D-C4EC-4BA1-8017-4FE9416123A8 Q36989546-AAC88669-AC06-4A5A-847A-21581E416849 Q37117151-A16A4847-6D7D-41FC-9EBE-C431C9913A1D Q37216946-17FAAB94-A9A6-4E7B-9CAB-782C08024D4D Q37322444-28B76C84-5B6F-46F2-888A-56ABAB9B693B Q37355086-D86D90A7-A8AB-4633-A33A-237332CD8192 Q37824265-F534C09E-D20A-455A-9AFD-BC5CD29C811C Q37885725-3A3D8980-5D1B-4FB7-BD68-032891C554E6 Q37889274-E4B4DEA3-2B82-418B-A43B-C58C621E2572 Q38019842-E2EE6286-3129-45A1-8513-91EDFF54EF8C

P2860

Evaluating HER2 amplification and overexpression in breast cancer.

http://www.wikidata.org/entity/Q52936177

description

2001 nî lūn-bûn

@nan

2001年の論文

@ja

2001年学术文章

@wuu

2001年学术文章

@zh

2001年学术文章

@zh-cn

2001年学术文章

@zh-hans

2001年学术文章

@zh-my

2001年学术文章

@zh-sg

2001年學術文章

@yue

2001年學術文章

@zh-hant

name

Evaluating HER2 amplification and overexpression in breast cancer.

@en

Evaluating HER2 amplification and overexpression in breast cancer.

@nl

type

label

Evaluating HER2 amplification and overexpression in breast cancer.

@en

Evaluating HER2 amplification and overexpression in breast cancer.

@nl

prefLabel

Evaluating HER2 amplification and overexpression in breast cancer.

@en

Evaluating HER2 amplification and overexpression in breast cancer.

@nl

P1433

Q52936177-78802EE9-B7BF-440F-8E36-00F529A580CF

P1476

Q52936177-F34E00E9-19D5-4FDD-BE0C-C9FA78571E95

P2093

Q52936177-0310930D-F37E-42D6-8599-EBA6E6F71EDD

Q52936177-311C261D-0D1C-4231-98C9-F4DDBFB563E9

Q52936177-A4C61551-8DFD-4C23-8327-A024474508A2

Q52936177-A8D9488C-E6D5-4E67-BE71-2B892336E3BF

Q52936177-AF68B02B-4E92-414A-A897-2535CD035C73

Q52936177-D971F10C-8655-4C27-ABBD-2479248353DE

Q52936177-EAC74B5F-38BB-413A-86F8-CEAB3860F35B

Q52936177-F070968A-6780-4704-A7BD-1AA7C9ADA09B

Q52936177-F46B3D0F-1B81-4893-A555-6E4544074D9D

P2860

Q52936177-12645B3B-4D73-41D1-B066-F932F3312349

Q52936177-14C4A887-42A2-489B-AFC5-CD930F11403E

Q52936177-39F74B14-7570-4222-9941-563A511A32F3

Q52936177-5ED5A15D-09EC-4A20-BDFD-EC0C3205CF25

Q52936177-6214873F-0C33-4377-98B8-20C14056930B

Q52936177-65F32F99-4C37-4F32-BD6A-FEB36CA1935E

Q52936177-67E37EAF-95A1-4ACD-AA99-FEB60AB8587D

Q52936177-76864A58-8393-4381-8E7C-46738110AA7B

Q52936177-A578E416-E2DF-49AC-9FF0-69CD5E573703

Q52936177-B8F9BFAD-92DB-4253-8719-5C7C7B067BEA

P304

Q52936177-2C0809CD-D441-4547-BE46-8B42CCB8294F

P31

Q52936177-600F91CD-682E-4A6A-ABD7-24C01D6FC36E

P356

Q52936177-EE45B1A1-B47B-4234-8C0E-48A960EE91A8

P433

Q52936177-C7B0F999-CCA3-4B1B-9091-6CF1D662BA3D

P478

Q52936177-F49ACD25-01C9-49D1-8EEA-E885819AD911

P50

Q52936177-232B05F5-DAAD-49E8-BC6E-E34B09540A2E

P577

Q52936177-FB07BFBD-2DC4-4E8C-8566-FE12AEDC23CE

P698

Q52936177-29337A2E-324C-4730-B100-471C853A129E

P921

Q52936177-8C5A19C0-B47B-43B3-AE59-78A78DA39400

P356

P1433

The Journal of Pathology

P1476

Evaluating HER2 amplification and overexpression in breast cancer.

@en

P2093

Bartlett JM

http://www.w3.org/2001/XMLSchema#string

Cooke TG

http://www.w3.org/2001/XMLSchema#string

Donald B

http://www.w3.org/2001/XMLSchema#string

Ferrier R

http://www.w3.org/2001/XMLSchema#string

Mallon EA

http://www.w3.org/2001/XMLSchema#string

Reeves JR

http://www.w3.org/2001/XMLSchema#string

Richmond J

http://www.w3.org/2001/XMLSchema#string

Stanton P

http://www.w3.org/2001/XMLSchema#string

Watters AD

http://www.w3.org/2001/XMLSchema#string

P2860

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer

Aneusomy of chromosomes 7 and 17 predicts the recurrence of transitional cell carcinoma of the urinary bladder.

Trastuzumab, a recombinant DNA-derived humanized monoclonal antibody, a novel agent for the treatment of metastatic breast cancer.

Recommendations for HER2 testing in the UK.

Is chromosome 9 loss a marker of disease recurrence in transitional cell carcinoma of the urinary bladder?

c-erbB-2 oncoprotein detected by automated quantitative immunocytochemistry in breast carcinomas correlates with patients' overall and disease-free survival.

Human squamous cell lung cancers express increased epidermal growth factor receptors.

Her-2/neu analysis in archival tissue samples of human breast cancer: comparison of immunohistochemistry and fluorescence in situ hybridization.

HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas.

P304

422-428

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/PATH.971

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

195

http://www.w3.org/2001/XMLSchema#string

P50

P577

2001-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

11745673

http://www.w3.org/2001/XMLSchema#string

P921